Outro Revisado por pares

Balance of Ischemia and Bleeding in Selecting Intensity and Duration of Antithrombotic Regimens

2022; Pulsus Group; Linguagem: Inglês

10.1002/9781119697367.ch43

ISSN

1755-5310

Autores

Davide Cao, Anton Camaj, Roxana Mehran,

Tópico(s)

Acute Myocardial Infarction Research

Resumo

Chapter 43 Balance of Ischemia and Bleeding in Selecting Intensity and Duration of Antithrombotic Regimens Davide Cao, Davide CaoSearch for more papers by this authorAnton Camaj, Anton CamajSearch for more papers by this authorRoxana Mehran, Roxana MehranSearch for more papers by this author Davide Cao, Davide CaoSearch for more papers by this authorAnton Camaj, Anton CamajSearch for more papers by this authorRoxana Mehran, Roxana MehranSearch for more papers by this author Book Editor(s):George D. Dangas MD, MACC, MSCAI, FAHA, FESC, George D. Dangas MD, MACC, MSCAI, FAHA, FESC Professor of Medicine (Cardiology) & Surgery (Vascular) Professor of Cardiology Adjunct Professor of Internal Medicine Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, NY, USA National Kapodistrian University of Athens, Greece Medical University of Vienna, AustriaSearch for more papers by this authorCarlo Di Mario MD, PhD, FRCP, FACC, FSCAI, FESC, Carlo Di Mario MD, PhD, FRCP, FACC, FSCAI, FESC Professor of Cardiology Director of the Structural Interventional Cardiology Division Honorary Consultant University of Florence University Hospital Careggi, Florence, Italy Cardiologist Royal Brompton Hospital, London, UKSearch for more papers by this authorHolger Thiele MD, Holger Thiele MD Professor of Cardiology at University of Leipzig Heart Center Leipzig at University of Leipzig, Leipzig, GermanySearch for more papers by this authorPeter Barlis MBBS, MPH, PHD, FACC, FESC, FRACP, Peter Barlis MBBS, MPH, PHD, FACC, FESC, FRACP Professor of Cardiology Interventional Cardiologist University of Melbourne, Melbourne, Victoria, Australia St Vincent's & Northern Hospitals Victoria, AustraliaSearch for more papers by this authorTayo Addo MD, Tayo Addo MD Dallas, TX, USASearch for more papers by this authorBimmer Claessen MD, Bimmer Claessen MD Amsterdam, NetherlandsSearch for more papers by this authorChristian Hengstenberg MD, Christian Hengstenberg MD Vienna, AustriaSearch for more papers by this authorNicholas Kipshidze MD, Nicholas Kipshidze MD New York, NY, USASearch for more papers by this author First published: 06 May 2022 https://doi.org/10.1002/9781119697367.ch43 AboutPDFPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Summary Percutaneous coronary intervention (PCI) is one of the most commonly performed therapeutic procedure worldwide. In this chapter, the authors aim to provide an overview of the pharmacologic treatment strategies aimed at optimizing the safety and efficacy of PCI in contemporary practice. Several risk prediction models have been developed to allow for risk stratification of patients undergoing PCI. Estimating the individual risk of ischemic and bleeding complications permits personalized clinical decision-making, which is paramount in selecting the appropriate antithrombotic treatment strategy. Continuous refinements in stent technology have allowed broadening the scope of PCI to increasingly challenging patient subsets which, although well represented in real-world practice, have generally been excluded or under-represented in randomized studies. Therefore, the ischemia-bleeding trade-off of short vs prolonged DAPT remains somewhat uncertain. Recent evidence suggests new opportunities of implementing point-of-care techniques to modulate the intensity of DAPT based on individual physiologic and genetic assessment of platelet reactivity. References Cutlip DE , Windecker S , Mehran R , et al . Clinical end points in coronary stent trials: a case for standardized definitions . Circulation 2007 ; 115 : 2344 – 51 . Garcia-Garcia HM , McFadden EP , Farb A , et al . Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document . Eur Heart J 2018 ; 39 : 2192 – 207 . Chesebro JH , Knatterud G , Roberts R , et al . Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge . Circulation 1987 ; 76 : 142 – 54 . GUSTO Investigators . An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction . N Engl J Med. 1993 ; 329 : 673 – 82 . Moscucci M , Fox KA , Cannon CP , et al . Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE) . Eur Heart J 2003 ; 24 : 1815 – 23 . Mehran R , Rao SV , Bhatt DL , et al . Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium . Circulation 2011 ; 123 : 2736 – 47 . Ndrepepa G , Schuster T , Hadamitzky M , et al . Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention . Circulation 2012 ; 125 : 1424 – 31 . Gori T , Polimeni A , Indolfi C , et al . Predictors of stent thrombosis and their implications for clinical practice . Nat Rev Cardiol 2019 ; 16 : 243 – 56 . Iakovou I , Schmidt T , Bonizzoni E , et al . Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents . JAMA 2005 ; 293 : 2126 – 30 . Jeremias A , Sylvia B , Bridges J , et al . Stent thrombosis after successful sirolimus-eluting stent implantation . Circulation 2004 ; 109 : 1930 – 2 . Park DW , Park SW , Park KH , et al . Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up . Am J Cardiol 2006 ; 98 : 352 – 6 . Genereux P , Rutledge DR , Palmerini T , et al . Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials . Circ Cardiovasc Interv 2015 ; 8 . Dangas GD , Claessen BE , Mehran R , et al . Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial . J Am Coll Cardiol 2012 ; 59 : 1752 – 9 . Kimura T , Morimoto T , Kozuma K , et al . Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: Observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART) . Circulation 2010 ; 122 : 52 – 61 . Lasala JM , Cox DA , Dobies D , et al . Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries . Circ Cardiovasc Intervent 2009 ; 2 : 285 – 93 . Ndrepepa G , Berger PB , Mehilli J , et al . Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point . J Am Coll Cardiol 2008 ; 51 : 690 – 7 . Eikelboom JW , Mehta SR , Anand SS , et al . Adverse impact of bleeding on prognosis in patients with acute coronary syndromes . Circulation 2006 ; 114 : 774 – 82 . Mehran R , Pocock S , Nikolsky E , et al . Impact of bleeding on mortality after percutaneous coronary intervention results from a patient–level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials . JACC Cardiovasc Interv 2011 ; 4 : 654 – 64 . Kikkert WJ , van Geloven N , van der Laan MH , et al . The prognostic value of bleeding academic research consortium (BARC)-defined bleeding complications in ST-segment elevation myocardial infarction: a comparison with the TIMI (Thrombolysis In Myocardial Infarction), GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries), and ISTH (International Society on Thrombosis and Haemostasis) bleeding classifications . J Am Coll Cardiol 2014 ; 63 : 1866 – 75 . Chhatriwalla AK , Amin AP , Kennedy KF , et al . Association between bleeding events and in-hospital mortality after percutaneous coronary intervention . JAMA 2013 ; 309 : 1022 – 9 . Kazi DS , Leong TK , Chang TI , et al . Association of spontaneous bleeding and myocardial infarction with long-term mortality after percutaneous coronary intervention . J Am Coll Cardiol 2015 ; 65 : 1411 – 20 . Mehran R , Pocock SJ , Stone GW , et al . Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial . Eur Heart J 2009 ; 30 : 1457 – 66 . Valgimigli M , Costa F , Lokhnygina Y , et al . Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial . Eur Heart J 2017 ; 38 : 804 – 10 . Suh JW , Mehran R , Claessen BE , et al . Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial . J Am Coll Cardiol 2011 ; 58 : 1750 – 6 . Wang TY , Xiao L , Alexander KP , et al . Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding . Circulation 2008 ; 118 : 2139 – 45 . Doyle BJ , Rihal CS , Gastineau DA , Holmes DR , Jr. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice . J Am Coll Cardiol 2009 ; 53 : 2019 – 27 . Granger CB , Goldberg RJ , Dabbous O , et al . Predictors of hospital mortality in the global registry of acute coronary events . Arch Intern Med 2003 ; 163 : 2345 – 53 . Antman EM , Cohen M , Bernink PJ , et al . The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making . JAMA 2000 ; 284 : 835 – 42 . Morrow DA , Antman EM , Charlesworth A , et al . TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy . Circulation 2000 ; 102 : 2031 – 7 . Suh J , Park DW , Lee JY , et al . The relationship and threshold of stent length with regard to risk of stent thrombosis after drug-eluting stent implantation . JACC Cardiovasc Interv 2010 ; 3 : 383 – 9 . van Werkum JW , Heestermans AA , Zomer AC , et al . Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry . J Am Coll Cardiol 2009 ; 53 : 1399 – 409 . Baber U , Kini AS , Sharma SK . Stenting of complex lesions: an overview . Nat Rev Cardiol 2010 ; 7 : 485 – 96 . Giustino G , Chieffo A , Palmerini T , et al . Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI . J Am Coll Cardiol 2016 ; 68 : 1851 – 64 . Yeh RW , Kereiakes DJ , Steg PG , et al . Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention . J Am Coll Cardiol 2017 ; 70 : 2213 – 23 . Valgimigli M , Bueno H , Byrne RA , et al . 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS) . Eur Heart J 2018 ; 39 : 213 – 60 . Levine GN , Bates ER , Bittl JA , et al . 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery . Circulation 2016 ; 134 : e123 – e55 . Mauri L , Kereiakes DJ , Yeh RW , et al . Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents . N Engl J Med 2014 ; 371 : 2155 – 66 . Yin SH , Xu P , Wang B , et al . Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis . BMJ 2019 ; 365 : l2222 . Yeh RW , Secemsky EA , Kereiakes DJ , et al . Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention . JAMA 2016 ; 315 : 1735 – 49 . Baber U , Mehran R , Giustino G , et al . Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS . J Am Coll Cardiol 2016 ; 67 : 2224 – 34 . Costa F , van Klaveren D , James S , et al . Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials . The Lancet 2017 ; 389 : 1025 – 34 . Abu-Assi E , Raposeiras-Roubin S , Cobas-Paz R , et al . Assessing the performance of the PRECISE-DAPT and PARIS risk scores for predicting one-year out-of-hospital bleeding in acute coronary syndrome patients . EuroIntervention 2018 ; 13 : 1914 – 22 . Song L , Guan C , Yan H , et al . Validation of contemporary risk scores in predicting coronary thrombotic events and major bleeding in patients with acute coronary syndrome after drug-eluting stent implantations . Catheter Cardiovasc Interv 2018 ; 91 : 573 – 81 . Bianco M , D'Ascenzo F , Raposeiras Roubin S , et al . Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor . Int J Cardiol 2020 ; 301 : 200 – 6 . Urban P , Mehran R , Colleran R , et al . Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention: A Consensus Document From the Academic Research Consortium for High Bleeding Risk . Circulation 2019 . 140 : 3 . Costa F , Van Klaveren D , Feres F , et al . Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting . J Am Coll Cardiol 2019 ; 73 : 741 – 54 . Bonaca MP , Bhatt DL , Cohen M , et al . Long-term use of ticagrelor in patients with prior myocardial infarction . N Engl J Med 2015 ; 372 : 1791 – 800 . Steg PG , Bhatt DL , Simon T , et al . Ticagrelor in Patients with Stable Coronary Disease and Diabetes . N Engl J Med 2019 ; 381 : 1309 – 20 . Bhatt DL , Steg PG , Mehta SR , et al . Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial . The Lancet 2019 ; 394 : 1169 – 80 . Mega JL , Braunwald E , Wiviott SD , et al . Rivaroxaban in patients with a recent acute coronary syndrome . N Engl J Med 2012 ; 366 : 9 – 19 . Alexander JH , Lopes RD , James S , et al . Apixaban with antiplatelet therapy after acute coronary syndrome . N Engl J Med 2011 ; 365 : 699 – 708 . Oldgren J , Budaj A , Granger CB , et al . Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial . Eur Heart J 2011 ; 32 : 2781 – 9 . Chiarito M , Cao D , Cannata F , et al . Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention After Acute Coronary Syndromes: A Systematic Review and Meta-analysis . JAMA Cardiol 2018 ; 3 : 234 – 41 . Gurbel PA , Bliden KP , Hiatt BL , O'Connor CM . Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity . Circulation 2003 ; 107 : 2908 – 13 . Mega JL , Close SL , Wiviott SD , et al . Cytochrome p-450 polymorphisms and response to clopidogrel . N Engl J Med 2009 ; 360 : 354 – 62 . Gurbel PA , Tantry US , Shuldiner AR , Kereiakes DJ . Genotyping: one piece of the puzzle to personalize antiplatelet therapy . J Am Coll Cardiol 2010 ; 56 : 112 – 6 . Sibbing D , Aradi D , Alexopoulos D , et al . Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention . JACC Cardiovasc Interv 2019 ; 12 : 1521 – 37 . Aradi D , Storey RF , Komócsi A , et al . Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention . Eur Heart J 2014 ; 35 : 209 – 15 . Parodi G , Marcucci R , Valenti R , et al . High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI . JAMA 2011 ; 306 : 1215 – 23 . Aradi D , Kirtane A , Bonello L , et al . Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention . Eur Heart J 2015 ; 36 : 1762 – 71 . Stone GW , Witzenbichler B , Weisz G , et al . Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study . The Lancet 2013 ; 382 : 614 – 23 . Price MJ , Berger PB , Teirstein PS , et al . Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial . JAMA 2011 ; 305 : 1097 – 105 . Collet JP , Cuisset T , Range G , et al . Bedside monitoring to adjust antiplatelet therapy for coronary stenting . N Engl J Med 2012 ; 367 : 2100 – 9 . Trenk D , Stone GW , Gawaz M , et al . A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study . J Am Coll Cardiol 2012 ; 59 : 2159 – 64 . Cayla G , Cuisset T , Silvain J , et al . Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial . The Lancet 2016 ; 388 : 2015 – 22 . Sibbing D , Aradi D , Jacobshagen C , et al . Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial . The Lancet 2017 ; 390 : 1747 – 57 . Mega JL , Simon T , Collet JP , et al . Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis . JAMA 2010 ; 304 : 1821 – 30 . Roberts JD , Wells GA , Le May MR , et al . Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial . The Lancet 2012 ; 379 : 1705 – 11 . Notarangelo FM , Maglietta G , Bevilacqua P , et al . Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes: The PHARMCLO Trial . J Am Coll Cardiol 2018 ; 71 : 1869 – 77 . Cavallari LH , Lee CR , Beitelshees AL , et al . Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention . JACC Cardiovasc Interv 2018 ; 11 : 181 – 91 . Claassens DMF , Vos GJA , Bergmeijer TO , et al . A Genotype-Guided Strategy for Oral P2Y(12) Inhibitors in Primary PCI . N Engl J Med 2019 ; 381 : 1621 – 31 . Pereira NL , Farkouh ME , So D , et al . Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial . JAMA 2020 ; 324 : 761 – 71 . Costa F , Valgimigli M . The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short . Cardio Diag Ther 2018 ; 8 : 630 – 46 . Urban P , Meredith IT , Abizaid A , et al . Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk . N Engl J Med 2015 ; 373 : 2038 – 47 . Ariotti S , Adamo M , Costa F , et al . Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial . JACC Cardiovasc Interv 2016 ; 9 : 426 – 36 . Varenne O , Cook S , Sideris G , et al . Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial . The Lancet 2018 ; 391 : 41 – 50 . Windecker S , Latib A , Kedhi E , et al . Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk . N Engl J Med 2020 . 382 : 1208 – 1218 DOI: 10.1056/NEJMoa1910021 Frigoli E , Smits P , Vranckx P , et al . Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study . Am Heart J 2019 ; 209 : 97 – 105 . Krucoff MW , Urban P , Tanguay JF , et al . Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents: The LF II Study . Circ Cardiovasc Interv 2020 ; 13 : e008603 . Mauri L , Kirtane AJ , Windecker S , et al . Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention . Am Heart J 2018 ; 205 : 110 – 7 . Valgimigli M , Cao D , Makkar RR , Bangalore S , Bhatt DL , Angiolillo DJ , Saito S , Ge J , Neumann FJ , Hermiller J , Picon H , Toelg R , Maksoud A , Chehab BM , Wang LJ , Wang J , Mehran R . Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent . Am Heart J. 2021 Jan; 231 : 147 – 156 . doi: 10.1016/j.ahj.2020.09.019 . Epub 2020 Oct 6. PMID: 33031789. Schömig A , Neumann FJ , Kastrati A , et al . A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents . N Engl J Med 1996 ; 334 : 1084 – 9 . Leon MB , Baim DS , Popma JJ , et al . A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators . N Engl J Med 1998 ; 339 : 1665 – 71 . Bertrand ME , Legrand V , Boland J , et al . Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study . Circulation 1998 ; 98 : 1597 – 603 . Bertrand ME , Rupprecht HJ , Urban P , Gershlick AH . Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS) . Circulation 2000 ; 102 : 624 – 9 . Mehta SR , Yusuf S , Peters RJ , et al . Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study . The Lancet 2001 ; 358 : 527 – 33 . Sabatine MS , Cannon CP , Gibson CM , et al . Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study . JAMA 2005 ; 294 : 1224 – 32 . Wiviott SD , Braunwald E , McCabe CH , et al . Prasugrel versus clopidogrel in patients with acute coronary syndromes . N Engl J Med 2007 ; 357 : 2001 – 15 . Wallentin L , Becker RC , Budaj A , et al . Ticagrelor versus clopidogrel in patients with acute coronary syndromes . N Engl J Med 2009 ; 361 : 1045 – 57 . Armstrong PC , Leadbeater PD , Chan MV , et al . In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation . J Thromb Haemost 2011 ; 9 : 552 – 61 . Mahaffey KW , Wojdyla DM , Carroll K , et al . Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial . Circulation 2011 ; 124 : 544 – 54 . Vranckx P , Valgimigli M , Juni P , et al . Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial . The Lancet 2018 ; 392 : 940 – 9 . Mehran R , Baber U , Sharma SK , et al . Ticagrelor with or without Aspirin in High-Risk Patients after PCI . N Engl J Med 2019 ; 381 : 2032 – 42 . Baber U , Zafar MU , Dangas G , et al . Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy . J Am Coll Cardiol 2020 ; 75 : 578 – 86 . Kim BK , Hong SJ , Cho YH , et al . Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial . JAMA 2020 ; 323 : 2407 – 16 . Hahn JY , Song YB , Oh JH , et al . Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial . JAMA 2019 ; 321 : 2428 – 37 . Watanabe H , Domei T , Morimoto T , et al . Effect of 1–Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial . JAMA 2019 ; 321 : 2414 – 27 . Dewilde WJ , Oirbans T , Verheugt FW , et al . Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial . The Lancet 2013 ; 381 : 1107 – 15 . Fiedler KA , Maeng M , Mehilli J , et al . Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial . J Am Coll Cardiol 2015 ; 65 : 1619 – 29 . Gibson CM , Mehran R , Bode C , et al . Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI . N Engl J Med 2016 ; 375 : 2423 – 34 . Cannon CP , Bhatt DL , Oldgren J , et al . Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation . N Engl J Med 2017 ; 377 : 1513 – 24 . Lopes RD , Heizer G , Aronson R , et al . Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation . N Engl J Med 2019 ; 380 : 1509 – 24 . Vranckx P , Valgimigli M , Eckardt L , et al . Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial . The Lancet 2019 ; 394 : 1335 – 43 . Gargiulo G , Goette A , Tijssen J , et al . Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials . Eur Heart J 2019 ; 40 : 3757 – 67 . Lopes RD , Hong H , Harskamp RE , et al . Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis . JAMA Cardiol 2020 . 5 ( 5 ): 582 – 589 . doi: 10.1001/jamacardio.2019.6175 Steffel J , Verhamme P , Potpara TS , et al . The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation . Eur Heart J 2018 ; 39 : 1330 – 93 . Angiolillo DJ , Goodman SG , Bhatt DL , et al . Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update . Circulation 2018 ; 138 : 527 – 36 . Hindricks G , Potpara T , Dagres N , et al . 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) . Eur Heart J 2020 . ehaa612, https://doi.org/10.1093/eurheartj/ehaa612 Cao D , Chandiramani R , Chiarito M , Claessen BE , Mehran R . Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey . Eur Heart J . 2020 Dec 26:ehaa824. doi: 10.1093/eurheartj/ehaa824 . Epub ahead of print. PMID: 33367641. Interventional Cardiology: Principles and Practice, Third Edition ReferencesRelatedInformation

Referência(s)
Altmetric
PlumX